SCHEMBL5218680

SCHEMBL5218680

O=C(O)c1csc(Nc2c(Cl)cccc2Cl)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.51
ALDH1A1 P00352 4/20 0.49
HPGD P15428 2/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.48
TRPC3 Q13507 1/20 0.44
TRPC6 Q9Y210 1/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 1/20 0.44
PLAU P00749 1/20 0.43
AMY1A P0DUB6 1/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217553 0.86 L3MBTL1 (0.50) KDM1ANPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL798528 0.85 NPC1 (0.77) KDM1ANPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL4926839 0.83 L3MBTL1 (0.54) KDM1ANPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL5215470 0.81 RAB9A (0.50) KDM1ANPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL2870272 0.80 KDM1A (0.78) KDM1ANPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL2285389 0.79 AMY1A (0.60) KDM1ANPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL14422241 0.78 KDM1A (0.55) KDM1ANPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL525682 0.78 KDM1A (0.76) KDM1ANPC1RAB9AALDH1A1HPGD
SCHEMBL525319 0.78 KDM1A (0.55) KDM1ANPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL525280 0.77 MEN1 (0.56) KDM1ANPC1RAB9AL3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1603905-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-12-14 EP disclosed
WO-2004072068-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-08-26 WO disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM1A 3163/4885NPC1 2453/4885RAB9A 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.